Loading…
Lobbying Spend
—
Filings
81
Firms Hired
2
Active Period
2007–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2212
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2017 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: S. 974
H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2212
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2017 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: S. 974
Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017, H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2212
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017, H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017, H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: S.934
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2017 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017, H.R. 2212-CREATES Act of 2017, S. 974-CREATES Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: S. 974
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Issues relating to the Biologics Price Competition and Innovation Act, Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Issues relating to the Biologics Price Competition and Innovation Act, Risk Evaluation Mitigation Strategies, industry user fees, S.934 - FDA Reauthorization Act of 2017, H.R. 2430-FDA Reauthorization Act of 2017
Client expense: — · Firm income: $50,000
Matched citations: S.934
21st Century Cures Act
2016 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Issues relating to the Biologics Price Competition and Innovation Act, S. 3056- CREATES Act of 2016, H.R. 34- 21st Century Cures Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 34
Issues relating to the Biologics Price Competition and Innovation Act, S. 3056- CREATES Act of 2016, H.R. 34- 21st Century Cures Act
Client expense: — · Firm income: $50,000
Matched citations: S. 3056
Implementation of the Biologics Price Competition and Innovation Act, S. 3056- CREATES Act of 2016
Client expense: — · Firm income: $50,000
Matched citations: S. 3056
Implementation of the Biologics Price Competition and Innovation Act, S. 3056- CREATES Act of 2016
Client expense: — · Firm income: $50,000
Matched citations: S. 3056
H.R. 9- Innovation Act, S. 1137- PATENT Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 9
H.R. 9- Innovation Act, S. 1137- PATENT Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1137
American Middle Class Tax (AMT) Relief Act of 2007
2010 · first_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK
Generic Biologics: H.R. 3590: Patient Protection and Affordable Care Act H.R. 4872: Health Care and Education Affordability Reconciliation Act of 2010
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3590
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)
Client expense: — · Firm income: $30,000
Matched citations: S. 726
American Middle Class Tax (AMT) Relief Act of 2007
2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK
Generic Biologics: -S. 726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R. 1548: Pathway for Biosimiliars Act -S. 1679 Affordable Health Choices Act -H.R. 3590:Patient Protection and Affordable Care Act -H.R. 3200: America's Affordable Health Choices Act of 2009 H.R. 3962: Affordable Health Care for America Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3590
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK
Generic Biologics: -S. 726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R. 1548: Pathway for Biosimiliars Act -S. 1679 Affordable Health Choices Act -H.R. 3590:Patient Protection and Affordable Care Act -H.R. 3200: America's Affordable Health Choices Act of 2009 H.R. 3962: Affordable Health Care for America Act
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1427
Source: Senate LDA